MedTrace Logo

Three-day, In-clinic Evaluation of the BD 2nd Generation Continuous Glucose Sensor Device in Type 1 Diabetics

NCT01645696 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-12-29

No results posted yet for this study

Summary

The purpose of this study is to investigate the accuracy and performance of a new subcutaneous continuous glucose monitor (BD-CGM, Becton Dickinson) in hyperglycemic (high blood sugar) and hypoglycemic (low blood sugar) "clamp" conditions and during meal excursions over the course of 72 hours as compared to a commercially available monitor.

Conditions

Interventions

DEVICE

BD CGM with Outer Layer

continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.

DEVICE

BD CGM without Outer Layer

continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.

DEVICE

Medtronic iPro2 Professional CGM

continuous subcutaneous glucose monitoring for 72 hours

Sponsors & Collaborators

  • Becton, Dickinson and Company

    lead INDUSTRY

Principal Investigators

  • Ronnie Aronson, MD · LMC Endocrinology Centre, Clinical Research Unit

Study Design

Allocation
NON_RANDOMIZED
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01645696 on ClinicalTrials.gov